Yet both Amgen and Johnson & Johnson avoided the outcome they most feared: a recommendation that the drugs not be used by any cancer patients.
Link to Article
NYTimes.com
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Search
Links
|
|||